Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin

Authors Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS

Published Date May 2013 Volume 2013:9 Pages 273—282


Received 21 February 2013, Accepted 20 March 2013, Published 29 May 2013

Helmut Steinberg, Matt S Anderson, Thomas Musliner, Mary E Hanson, Samuel S Engel

Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA

Abstract: The risk of death due to heart disease and stroke is up to four times higher in individuals with diabetes compared to individuals without diabetes. Most guidelines that address treatment of dyslipidemia in patients with diabetes consider diabetes a cardiovascular disease (CVD) "risk equivalent" and recommend intensive treatment of dyslipidemia for the purpose of CVD prevention. Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase [HMG-CoA reductase] inhibitors) are first-line agents in achieving lipid goals as an adjunct to diet and exercise and should be used in most patients. In addition to lipid management and blood pressure control, glycemic control is a basic component in the management of diabetes. Glycemic control is achieved by combining diabetes self-management education, diet and exercise, and, where required, antihyperglycemic agents (OHAs). Persistence and adherence to therapy are critical in achieving recommended treatment goals. However, overall compliance with concomitantly prescribed OHAs and statins is low in patients with type 2 diabetes. Fixed-dose combination (FDC) therapies have been shown to improve adherence by reducing pill burden, the complexity of treatment regimen, and, potentially, cost. Based on the available evidence regarding the pharmacokinetics and the efficacy and safety profiles of each component drug, the sitagliptin/simvastatin FDC may provide a rational and well-tolerated approach to achieving better adherence to multiple-drug therapy and improved lipid lowering and glycemic control, with consequent reduction in cardiovascular risk, diabetic microvascular disease, and mortality in diabetic patients for whom treatment with both compounds is appropriate.

Keywords: statin, oral antihyperglycemic agent, diabetes, adherence, cardiovascular disease, microvascular disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab

Cavallini GM, Pellegrini G, Volante V, Ducange P, De Maria M, Torlai G, Benatti C, Forlini M

Clinical Ophthalmology 2014, 8:1671-1673

Published Date: 30 August 2014

Acute toxicity of nickel nanoparticles in rats after intravenous injection

Magaye RR, Yue X, Zou B, Shi H, Yu H, Liu K, Lin X, Xu J, Yang C, Wu A, Zhao J

International Journal of Nanomedicine 2014, 9:1393-1402

Published Date: 12 March 2014

Umbilical cord mesenchymal stem cells labeled with multimodal iron oxide nanoparticles with fluorescent and magnetic properties: application for in vivo cell tracking

Sibov TT, Pavon LF, Miyaki LA, Mamani JB, Nucci LP, Alvarim LT, Silveira PH, Marti LC, Gamarra LF

International Journal of Nanomedicine 2014, 9:337-350

Published Date: 8 January 2014

Anti-obesity efficacy of nanoemulsion oleoresin capsicum in obese rats fed a high-fat diet

Kim JY, Lee MS, Jung S, Joo H, Kim CT, Kim IH, Seo S, Oh S, Kim Y

International Journal of Nanomedicine 2014, 9:301-310

Published Date: 3 January 2014

Nanostructured systems containing babassu (Orbignya speciosa) oil as a potential alternative therapy for benign prostatic hyperplasia

de Sousa VP, Crean J, Borges VRA, Rodrigues CR, Tajber L, Boylan F, Cabral LM

International Journal of Nanomedicine 2013, 8:3129-3139

Published Date: 15 August 2013

In vivo evaluation of a conjugated poly(lactide-ethylene glycol) nanoparticle depot formulation for prolonged insulin delivery in the diabetic rabbit model

Tomar L, Tyagi C, Kumar M, Kumar P, Singh H, Choonara YE, Pillay V

International Journal of Nanomedicine 2013, 8:505-520

Published Date: 4 February 2013

Squamous cell papilloma of the conjunctiva due to human papillomavirus (HPV): presentation of two cases and review of literature

Kalogeropoulos C, Koumpoulis I, Papadiotis E, Zioga A, Gkrepi K, Pappa C, Paschides C, Malamou-Mitsi V, Aspiotis M

Clinical Ophthalmology 2012, 6:1553-1561

Published Date: 24 September 2012